Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib.
Elena BolzacchiniMonica GiordanoLorenza BertùMarco BregniOlga NigroLuca GalliAndrea AntonuzzoSalvatore ArtaleSabrina BarzaghiMarco DanovaMartina TorchioGraziella PinottiFrancesco DentaliPublished in: Tumori (2021)
In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.